Page last updated: 2024-08-24

topotecan and regorafenib

topotecan has been researched along with regorafenib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Al-Rihani, SB; Ambudkar, SV; Chen, ZS; Kaddoumi, A; Lei, ZN; Shi, Z; Shukla, S; Wang, DS; Wang, YJ; Zhang, GN; Zhang, XY; Zhang, YK	1

Other Studies

2 other study(ies) available for topotecan and regorafenib

Article	Year
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer. Cancer letters, 2019, 02-01, Volume: 442 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; Binding Sites; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Mice, Nude; Mitoxantrone; Molecular Docking Simulation; Molecular Dynamics Simulation; Neoplasm Proteins; Phenylurea Compounds; Protein Binding; Protein Conformation; Pyridines; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays	2019

Article

Year

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013

Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.

Cancer letters, 2019, 02-01, Volume: 442

Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; Binding Sites; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Mice, Nude; Mitoxantrone; Molecular Docking Simulation; Molecular Dynamics Simulation; Neoplasm Proteins; Phenylurea Compounds; Protein Binding; Protein Conformation; Pyridines; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays

2019